Member Info for olderbutwiser

This mornings little flurry of buys is probably down to Sunday Times article on the front page of the business section.

Extracts below:

'GSK set for multibillion pound buying spree of respiratory businesses as it seeks to reassure investors about its lacklustre pipeline.

According to Luke Miels, Chief Commercial Officer, over the next six months GSK would be concentrating on deals worth about £1.6 billion.

Its priority would be buying businesses with respiratory and auto-immune treatments.

Miels ruled out deals in the the "tens of billions" of dollars and said GSK was more focused on "very targeted single products and two products in a company".

NFTs is strangely quiet today!

I wonder why.

I know - below the belt - I wouldn't normally but possibly a dose of karma?

look again dumb-****.

looks like someone sensible has done a bed and breakfast and moved shares from an ordinary share account into their isa account.

prudent to minimise tax liability for when these go up massively on imminent news.

If Statler and Waldorf had a love child with Eeyore then its name would have to be ForFXSake.

C’mon give us a few moments of misconceived optimism before you throw your usual bucket of cold sick over everyone.

So I guess you must be going to the AGM to air your comments directly with the directors!

Forgot to say that Insilico's drug is an oral treatment not inhaled - so much higher risk of systemic toxicity and unwanted side effects.

'Their randomised, double-blind, placebo-controlled, clinical trial will assess the safety, tolerability, pharmacokinetics (PKs), and preliminary efficacy of a 12-week oral dosage of INS018_055 in patients with IPF. This trial will have four cohorts, with patients receiving 30mg once-daily (QD), 30mg twice-daily (BID), 60mg QD doses or placebo.'

In this 2021 report 'Fibrotic Pattern Detection by (AI) Artificial Intelligence identified tranilast as an effective (IPF) inhibitor '.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694600/

Just search for 'tranilast' in the text.

Hi Soupdragon78 keep up the good work re info.

Re availability of tissue to complete the last Fibrofind studies.

The question was asked at the Q&A session - about 49 minutes in - and Dan said that Fibrofind now had a relationship with Papworth and that they now have a 'vastly increased access to the right kind of tissue'.

So hopefully a much reduced timescale.

Hi Soup - my point was a minor one of clarification of who puts out the TR1 - I understand the 'insti' has to notify the FCA and the FCA system automatically puts out the RNS. The 'insti' then has to inform the issuer separately and after as follows.
'Shareholders and holders of financial instruments falling within DTR 5.3.1R(1) should inform an issuer whose shares are admitted to trading on a UK regulated market (such as the Main Market of the London Stock Exchange) by emailing/forwarding the issuer a downloaded copy of the electronic TR-1 Form (DOC) obtainable once the submission to the FCA has been completed on the ESS.'
As with everything in the market there is no real transparency despite what the FCA claim!
Good luck all.

I gather that the onus is on the institution to notify the FCA of their holding if they have a notifiable holding. and that is done via the electronic Standard form for notification of major holdings (TR–1 Form) contained within the ‘Major Shareholding Notification’ portal on the FCA’s Electronic Submission System (ESS).
I believe the TR1 RNS is automatically put out by the FCA system and that Nuformix are not involved.
Lanstead's TR1 certainly shows us that, in this instance, Lanstead have been very quick in notifying the FCA.
It is not uncommon for TR1's to be a week or two after the event.
It is certainly a growing possibility that the 'insti' does not have a notifiable interest BUT there is still a possibility that they are just slow in notifying.

Overall, the results provide further support of NXP002's potential to increase efficacy of existing therapies with the benefits of inhaled delivery (e.g. added efficacy without increased side effects). They also support NXP002's potential as a monotherapy for patients declining SoCs - a meaningful proportion of IPF patients who choose against the side effects of SoCs, which impact quality of life.

Think your right FXS - think there is a general problem for small companies due to change in accountancy rules in last year..
I don't see it as an issue for concern unless people want it to be.

Article in yesterdays Sunday Times business section about large pharma companies worried that a huge amount of their revenues could disappear in the next 5 to 7 years due to patent expiry.
Says these companies are rushing to develop new drugs or buy up smaller promising companies.
Names Astra Zeneca’s Lynparza (Olaparib) with sales of £2.6 billion in 2021 as coming off-patent in 2028 with two more major Astra drugs coming off-patent in 2029.
Now does anybody know of a small company with drug patents relevant to Astra Zeneca?

NFTs you have chosen a rather extreme example of a fund raising - any particular reason why?.
Currently Yourgene have 727 million shares and the proposed fundraise will add a further 2,000 million shares making a future total of 2,727 Million shares and they are doing this in order to raise a total of £6 million. So I am not surprised that the Yourgene share price dropped by 80%.

Thanks Soup - i missed the other mistake from Dan re quoting program names.
So according to Dan the extra (nxp004) data needed to start out-licensing is really quick and cheap to generate. So out-licensing discussions potentially starting quite soon by the sounds of it. Shame he didn't include that info in today's RNS.
Things are really looking up - and about time.

Did Dan mis-quote and say nxp4 when he mean nxp2 and then vice versa in the interview, or am I missing something?
Really excellent news today.

I think Dan swapped NXP2 and NXP4 in his Proactive interview? NXP4 as inhaled therapy?
Below is exact transcription of part of the interview!
"Question from interviewer – What does this all mean for investors?
The key thing that investors want to know and understand is when are we getting into licensing discussions – and that’s exactly the space I want to get into.
If we look at NXP4 we have there a product where we are looking to develop an inhaled therapy for really complex disease and we’re working with a virtual team of advisers who are really prominent in the sector. The kind of level of validation of this product and the scrutiny it is going to attract prior to out-licensing is really quite high, but working with those advisors we’ve identified the minimum data set we need to generate, which we believe is the minimum requirement for really opening out-licensing discussions in detail. So we have initiated that work and that’s all funded out of existing funds. So that aspect is on track.
NXP2 is a really different program. Yes we’re in a situation where more data is required in order to start those out-licensing discussions but this data is really quick and cheap to generate, the data from today’s announcement kind of supports our decision to progress this program to that next stage and data from that should be the minimum requirement for out-licensing discussions."

Good find Soupdragon - and only published a few days ago.
Good to see the Lancet discovery science say how promising Tranilast is as a treatment.
Those who went to the ERS will also know that NXP002 is the inhaled version of Tranilast optimised for lung therapy and which overcomes the known serious side effects of oral Tranilast.
Yet more confirmation of what Dan said in the last RNS:
• Fortunately, we are in a moment where those (pharma) trends are converging with our programme, our enhanced IP position and our access to a new, close-to-patient, disease relevant model.
• The prospect of increased efficacy with improved quality of life for IPF patients is a realistic possibility for NXP002 combination therapies based on our existing pilot human IPF tissue data.
• I am confident that our revised pre-clinical strategy will maximise the value of our IP estate and will generate further compelling data to support both progression and partnering of NXP002.
• I look forward to providing further updates throughout the remainder of the year."

'they trying to push the “but it’s great in combination” with no data shown to prove it'.
Well we are most fortunate to have such a knowledgeable poster as Mulder on the board.
Obviously he knows much more than Dr Lee Borthwick, Senior Lecturer in Fibrosis Biology at the Newcastle Fibrosis Research Group, Newcastle University who oversaw the combination trials with NXP002.
Perhaps Mulder could tell us why Dr Lee Borthwick is talking out his backside?!

Agree filter - Certainly looks like the pound and the economy are being 'flushed down the kwasi'.
CPI or Lanstead selling down?
Possibly.
Or does the timing suggest that it is some pi's baling on seeing our new chancellor abandon all fiscal common-sense.
I can only assume he is lining up for a big job in the city in the near future.
About 9 million sells on friday afternoon and about 3 million sells yesterday afternoon - so hopefully it will taper off.

OFEV (Nintedanib) and Esbriet (Pirfenidone) will be overtaken by generics and their prices will drop - but it will be NXP002 that will be the drug providing the significantly improved efficacy - allowing lower doses of Nintedanib or Pirfenidone and providing the markedly improved patient outcomes with significantly less side effects.
NXP002 will be patent protected and has the potential to become a new blockbuster. Licensees will be keen to get their hands on the Nuformix patents – especially the latest patent filed (very stealthily) earlier this year.
I am sure Roche and other potential licensees can see the huge commercial opportunities NXP002 now offers and possibly how they can also use it to extend their own drug patent life.